Back to Search
Start Over
Pyruvate kinase type tumor M2 in urological malignancies
- Source :
- Urologia internationalis. 70(1)
- Publication Year :
- 2001
-
Abstract
- Introduction: The dimeric form of pyruvate kinase type M2 is overexpressed in tumor cells (TuM2-PK). The aim of the present study was to evaluate the clinical value of TuM2-PK as a tumor marker for renal cell carcinoma (RCC), transitional cell carcinoma of the bladder (TCC) and prostate cancer (PCA) by using a commercially available enzyme-linked immunosorbent assay for detection of TuM2-PK in plasma. Material and Methods: The TuM2-PK concentration in EDTA plasma was determined quantitatively and immunologically using an ELISA (ScheBo®Tech, Germany). We measured the TuM2-PK plasma levels of 83 patients with RCC, 30 patients with TCC and 30 patients with PCA before any therapy. 100 patients with various non-malignant urological disorders were recruited as the control group. Results: Only patients with RCC showed significantly elevated plasma levels of TuM2-PK compared to the control group (p < 0.01). We found a sensitivity of 42.6% and a specificity of 80.4% using a cut-off value of 15 U/ml (manufacturer’s recommendation). During follow-up, only 50% showed increasing plasma levels of TuM2-PK in case of metastases. Significant differences could not be detected in either TCC or PCA. Conclusions: Our data suggest that TuM2-PK is not a useful marker for TCC and PCA. Due to low sensitivity and specificity, TuM2-PK is not suitable for the diagnosis of RCC. Whether TuM2-PK may be useful in advanced RCC to control success of palliative treatment regimens is still unclear.
- Subjects :
- Male
Pathology
medicine.medical_specialty
Urologic Neoplasms
Urology
Pyruvate Kinase
Tumor M2-PK
Enzyme-Linked Immunosorbent Assay
urologic and male genital diseases
Sensitivity and Specificity
Cohort Studies
Prostate cancer
Prostate
Renal cell carcinoma
Reference Values
medicine
Carcinoma
Biomarkers, Tumor
Humans
Carcinoma, Renal Cell
Tumor marker
Aged
Neoplasm Staging
Aged, 80 and over
Carcinoma, Transitional Cell
business.industry
Prostatic Neoplasms
Middle Aged
medicine.disease
Prognosis
female genital diseases and pregnancy complications
Kidney Neoplasms
Survival Rate
medicine.anatomical_structure
Transitional cell carcinoma
Urinary Bladder Neoplasms
Case-Control Studies
Cancer research
Adenocarcinoma
Female
business
Subjects
Details
- ISSN :
- 00421138
- Volume :
- 70
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Urologia internationalis
- Accession number :
- edsair.doi.dedup.....88443bce7977e4e8bbd1f73ba10ee539